<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04212910</url>
  </required_header>
  <id_info>
    <org_study_id>PET/MRI-ONCOGYN</org_study_id>
    <nct_id>NCT04212910</nct_id>
  </id_info>
  <brief_title>Stratifying Endometrial Cancer Patients Using a PET/MRI Prognostic Model</brief_title>
  <official_title>Stratifying Endometrial Cancer Patients Using a PET/MRI Prognostic Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endometrial cancer (EC) is the most common gynecological malignancy in high-income countries.
      Prognosis and treatment are dictated by cancer histological subtype and grade coupled with
      surgical staging as described by Surgical International Federation of Gynecology and
      Obstetrics (FIGO) staging system. Surgery is the elective standard treatment and used for
      staging of EC. The purpose of this study is to collect images from a simultaneous PET/MRI
      study from which to extrapolate a preoperative, non-invasive, prognostic model.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Magnetic resonance imaging (MRI) is the most frequently used imaging tool in preoperative
      staging of endometrial cancer. FDG-PET has demonstrated higher sensitivity than MRI in
      detecting nodal involvement and metastatic disease and is currently used in adjunction to
      MRI. Distinct MRI and FDG-PET parameters correlate well with tumor aggressiveness and can and
      have been used as prognostic factors. The Investigators believe that the combination of data
      from these two imaging techniques, from which different derived tumor features can be
      extrapolated, can stratify patients in high-risk and low-risk groups already preoperatively.
      The aim of combined techniques is to collect large amounts of data leveraging advantages of
      both modalities (MR's strengths in local staging and PET's strengths in nodal staging) in a
      single scan from which to extrapolate a preoperative, non-invasive, prognostic model.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Anticipated">July 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 23, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MRI imaging evaluation</measure>
    <time_frame>0-2 years</time_frame>
    <description>Measure tumor volume and correlate to surgical specimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI imaging evaluation</measure>
    <time_frame>0-2 years</time_frame>
    <description>Changes in ADC normale versus tumor myometrium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI imaging evaluation</measure>
    <time_frame>0-2 years</time_frame>
    <description>Depth of myometrial invasion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DCE-MRI perfusion parameters</measure>
    <time_frame>0-2 years</time_frame>
    <description>Define tumor perfusion in normal versus tumor myometrium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI imaging evaluation</measure>
    <time_frame>0-2 years</time_frame>
    <description>positive lymph node evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PET imaging evaluation</measure>
    <time_frame>0-2 years</time_frame>
    <description>PET positive lymph nodes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PET imaging evaluation</measure>
    <time_frame>0-2 years</time_frame>
    <description>Tumor/positive lymph node/metastases SUV values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure tumor angiogenesis</measure>
    <time_frame>0-2 years</time_frame>
    <description>angiogenesis marker, CD1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate PET and MRI derived functional and morphological parameters with histology</measure>
    <time_frame>0-5 years</time_frame>
    <description>Imaging derived parameters correlated with histopathology</description>
  </secondary_outcome>
  <enrollment type="Anticipated">101</enrollment>
  <condition>Endometrium Cancer</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Surgically removed endometrium and lymphnodes
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with biopsy proven endometrial cancer presenting to the Institution's Gynecology
        Unit.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histopathological confirmation of a primary endometrial cancer

          -  age &gt; 18 years

          -  no contraindication to surgery (comorbidity, contraindication or lack of consent)

          -  no contraindication to preoperative imaging

          -  visible tumor at imaging

          -  signed inform consent.

        Exclusion Criteria:

          -  patients unsuitable for surgical intervention (comorbidity, contraindication or lack
             of consent, poor performance status)

          -  age &lt; 18 years, c) inability to complete the needed imaging examination (ie, severe
             claustrophobia)

          -  any additional medical condition that may significantly interfere with study
             compliance

          -  all the contraindication for MRI (ie, pacemaker).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females patients with endometrial cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stephanie Steidler, PhD</last_name>
    <phone>+39022643</phone>
    <phone_ext>6111</phone_ext>
    <email>steidler.stephanie@hsr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Steidler</last_name>
      <email>steidler.stephanie@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Gabriele Ironi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice Bergamini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Kitajima K, Kita M, Suzuki K, Senda M, Nakamoto Y, Sugimura K. Prognostic significance of SUVmax (maximum standardized uptake value) measured by [¹⁸F]FDG PET/CT in endometrial cancer. Eur J Nucl Med Mol Imaging. 2012 May;39(5):840-5. doi: 10.1007/s00259-011-2057-9. Epub 2012 Feb 17.</citation>
    <PMID>22349717</PMID>
  </reference>
  <reference>
    <citation>Nakamura K, Kodama J, Okumura Y, Hongo A, Kanazawa S, Hiramatsu Y. The SUVmax of 18F-FDG PET correlates with histological grade in endometrial cancer. Int J Gynecol Cancer. 2010 Jan;20(1):110-5. doi: 10.1111/IGC.0b013e3181c3a288.</citation>
    <PMID>20130510</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 24, 2019</study_first_submitted>
  <study_first_submitted_qc>December 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2019</study_first_posted>
  <last_update_submitted>December 25, 2019</last_update_submitted>
  <last_update_submitted_qc>December 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Francesco De Cobelli</investigator_full_name>
    <investigator_title>Head, Radiology Department</investigator_title>
  </responsible_party>
  <keyword>endometrium</keyword>
  <keyword>cancer</keyword>
  <keyword>PET-MRI</keyword>
  <keyword>stratification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

